Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Actinium Pharmaceuticals, Inc.

Actinium is developing a pipeline of Antibody Radiation Conjugates for targeted conditioning and combination therapies.

Actinium Pharmaceuticals, Inc. | 13,072 followers on LinkedIn. Targeted Therapies for Patients with Unmet Needs | Actinium Pharmaceuticals (NYSE: ATNM) is focused on developing innovative targeted radioimmunotherapies for the treatment of advanced cancers. Currently Investigating therapies in #AML and #BMT

Vice President, Patent and Legal Counsel at Actinium Pharmaceuticals, Inc.

Paul Diamond

Biotech Executive | Finance & Operations | Biotech Growth Specialist | Vice President, Finance @ Actinium Pharmaceuticals

Steve Dressel

Gary Siegel

Chief Business Officer

Lynn Bodarky

Actinium Pharmaceuticals (NYSE: ATNM) Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors. Read the press release here: https://bit.ly/4eftEdy

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology. Read the press release here: https://bit.ly/3MOAuf4 #AML #Radiotherapies

Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. Read the press release here: https://bit.ly/3Ad5jXP

Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted #Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications. Read the press release here: https://bit.ly/3A2I02C #CARTcelltherapy #CellTherapy

Actinium (NYSE: ATNM) Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for #SickleCellDisease Patients Undergoing #BoneMarrowTransplant in Collaboration with Columbia University. Read the press release here: https://bit.ly/3A8BnvC #BMT

Actinium Pharmaceuticals (NYSE: ATNM) to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US. Read the press release here: https://bit.ly/3YfmQZ9 #Radiotherapy

#EHA2024 recap: Abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium's ARC Actimab-A in acute myeloid leukemia (AML) models. Results available here: https://bit.ly/3VJRDLX

#EHA2024 presentation recap: median overall survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic #bonemarrowtransplant compared to 1.66 months in patients that did not receive Iomab-B in Phase 3 SIERRA Trial. More details here: https://lnkd.in/gBJF3HT3

Actimab-A is an ARC comprised of a CD33 targeting monoclonal antibody conjugated with the alpha-particle emitter Actinium-225 isotope payload. Read recent data presented at #SNMMI24 as we advance our Actimab program: https://bit.ly/3Ro0ikZ

Actinium recently announced the long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the Phase 3 SIERRA trial. Read more here: https://bit.ly/3VqCTQL #Oncology #EHA2024 #Radiotherapies

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover									0.01 -	0.01 36.62%	0.00 88.97%
cash per share	7.30 -	7.37 0.95%	20.16 173.72%	12.70 37.00%	7.82 38.43%	3.87 50.54%	1.86 51.92%	5.24 181.65%	3.78 27.76%	4.51 19.22%	288.22 6,288.74%
company equity multiplier	-3.70 -	-3.94 6.49%	1.21 130.73%	1.25 3.39%	1.34 7.22%	1.69 25.96%	2.07 22.38%	1.08 47.63%	1.09 0.94%	1.72 57.14%	2.24 30.34%
days of inventory outstanding
days of payables outstanding	33.56K -
days of sales outstanding
dividend yield							0.00 -	0.00 72.94%
ebit per revenue									-21.82 -	-33.11 51.73%	-640.99 1,835.89%
ebt per ebit	1.63 -	1.10 32.81%	0.85 22.89%	0.91 6.98%	0.99 9.12%	0.99 0.43%	0.99 0.05%	0.99 0.01%	0.99 0.03%	0.97 2.44%	0.94 2.88%
effective tax rate	-0.00 -	-0.00 84.93%	-0.00 966.80%	-0.00 44.99%	0.01 5,752.62%	-0.01 162.98%	0.01 207.41%	0.01 1.78%	0.01 4.28%	0.03 329.27%
enterprise value multiple	-19.53 -	-6.90 64.70%	-3.95 42.71%	-0.82 79.30%	-0.99 21.12%	-1.16 17.34%	-1.14 1.94%	-1.45 27.27%	-1.89 30.06%	-4.51 139.31%	1.41 131.24%
fixed asset turnover									1.79 -	0.35 80.48%	0.03 91.92%
free cash flow per share	-8.32 -	-15.90 91.11%	-14.62 8.06%	-12.91 11.70%	-9.70 24.85%	-5.85 39.71%	-4.33 26.01%	-1.80 58.34%	-1.02 43.35%	0.34 133.59%	-178.50 52,156.69%
gross profit margin									1 -	1 0%	1 0%
interest coverage	-2.63K -	-25.96K 887.66%	-3.16K 87.84%	-5.36K 69.91%	-4.96K 7.57%	-137.44 97.23%				31.37 -
inventory turnover
long term debt to capitalization						0.00 -	0.11 7,027.87%	0.01 95.32%	0.00 99.19%	0.03 74,380.53%	0.04 36.34%
net income per ebt	1 -	1 0%	1 0%	1 0%	1 0%	1 0%	0.99 0.79%	0.99 0.01%	0.99 0.03%	0.97 2.54%	1 3.40%
net profit margin									-21.49 -	-31 44.26%	-602.69 1,844.17%
operating cash flow per share	-8.30 -	-15.73 89.61%	-14.58 7.32%	-12.87 11.73%	-9.69 24.72%	-5.82 39.93%	-4.31 25.89%	-1.78 58.70%	-1.01 43.05%	0.36 135.29%	-177.92 49,791.92%
operating profit margin									-21.82 -	-33.11 51.73%	-640.99 1,835.89%
payables turnover	0.01 -
pretax profit margin									-21.66 -	-32.06 48.02%	-602.69 1,780.16%
price fair value	-85.93 -	-83.83 2.44%	5.61 106.69%	2.35 58.02%	3.24 37.59%	4.66 43.73%	5.76 23.64%	1.54 73.19%	1.68 8.90%	3.87 130.09%	0.04 99.04%
receivables turnover
return on assets	-1.87 -	-3.26 74.55%	-0.79 75.75%	-1.08 36.52%	-1.45 34.37%	-1.59 9.51%	-1.86 17.19%	-0.33 82.17%	-0.31 7.86%	-0.28 8.57%	-0.60 114.36%
return on capital employed	4.23 -	11.69 176.64%	-1.13 109.66%	-1.49 31.94%	-1.97 32.04%	-2.70 37.15%	-3.49 29.22%	-0.36 89.58%	-0.34 6.58%	-0.33 2.98%	-0.71 116.13%
return on equity	6.91 -	12.84 85.88%	-0.96 107.45%	-1.35 41.15%	-1.95 44.07%	-2.68 37.94%	-3.85 43.41%	-0.36 90.66%	-0.33 6.99%	-0.48 43.68%	-1.34 179.40%
total debt to capitalization	-0.11 -	-0.17 53.65%	0.01 106.91%			0.03 -	0.20 597.86%	0.01 94.11%	0.00 64.70%	0.04 790.36%	0.05 46.89%

COM:ACTINIUMPHARMA

Actinium Pharmaceuticals, Inc.

Last Close

1.47

22/11 21:00

Market Cap

210.57M

Beta: -

Volume Today

222.68K

Avg: -

Preview